title: Clinical significance of side population in ovarian cancer cells.
abstract: Recently, accumulating evidence has suggested that tumors, including ovarian cancer, are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth. The emergence of drug resistance is one of the most difficult problems in the treatment of ovarian cancer, which has been explained recently by the potential of CSCs to have superior resistance against anti-cancer drugs than conventional cancer cells. In this study, we expanded this line of study to examine whether this phenomenon is also observed in clinical specimens of ovarian cancer cells. In total we could analyze 28 samples out of 60 obtained from ovarian cancer patients. The clinical samples were subjected to testing of the expression of side population (SP) as a CSC marker, and according to the presence of SP (SP+) or absence of SP (SP-), clinicopathological significances were analyzed. Although there was no statistical significance, there were more SP+s in recurrent cases as well as in ascitic and peritoneal dissemination than in primary tumor of the ovary. There was no correlation between SP status and FIGO staging. In 19 cases of those who could be followed more than 6 months from initial therapy, there were 8 cases of recurrence or death from disease, and all of these were SP+. On the other hand, in 11 cases of disease-free survivors, 6 were SP+. There was a significant difference in prognosis between SP+ and SP- (p = 0.017). Although this study was limited, it revealed that SP could be contained more in recurrent or metastatic tumors than in primary tumors, and also that the presence of SP could be a risk factor of recurrence in ovarian cancer. Therefore, a novel therapeutic strategy targeting SP could improve the prognosis of ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Miyamae-ku, Kawasaki, Kanagawa, Japan.
authors.forename: Shinji
authors.initials: S
authors.lastname: Hosonuma
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kojo
authors.forename: Haruka
authors.initials: H
authors.lastname: Wada
authors.forename: Ken-ichiro
authors.initials: K
authors.lastname: Seino
authors.forename: Kazushige
authors.initials: K
authors.lastname: Kiguchi
authors.forename: Bunpei
authors.initials: B
authors.lastname: Ishizuka
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging / Q000379:methods; D014411:Neoplastic Stem Cells / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D058985:Side-Population Cells / Q000473:pathology*